Correction to: Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib.

The original article can be found online.

Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib.

Background: This prospective, post-marketing observational study in Japanese patients aimed to evaluate the safety and effectiveness of daily afatinib use in general practice.

Methods: This non-interventional study (NCT02131259) enrolled treatment-naïve and pre-treated patients with inoperable/recurrent EGFR mutation-positive NSCLC, eligible for afatinib treatment as per the afatinib label in Japan. Patients received afatinib at the approved dose (20, 30, 40, or 50 mg/day; physician decision), and were observed following treatment initiation for 52 weeks or until premature discontinuation.

Controlled spatial separation of Eu ions in layered silicates with different layer thickness.

The photoluminescence of a series of Eu(3+) doped layered silicates (kanemite, octosilicate, magadiite and kenyaite) was examined; it was found that layer thickness affected the luminescence intensity, suggesting the possible effects of the spatial separation of Eu(3+) in the direction perpendicular to silicate sheets on the luminescence self-quenching.